Otonomy, Inc.: Series B $38.5M

Posted in I - Series B, Q - 3Q10, R - WEST, X - Hearing Loss, X - Ménière's, X - Tinnitus, XX - CA

Otonomy (San Diego, CA) a clinical-stage biopharmaceutical company focused on, hearing and balance disorders such as Ménière’s disease, hearing loss, and tinnitus. closed a $38.5M Series B financing. Participants include Novo Ventures, RiverVest Venture Partners, Domain Associates and TPG Biotech.

Aptus Endosystems, Inc.: Series D $15

Posted in I - Series D, Q - 3Q10, R - WEST, X - Device (Aneurysm), XX - CA

Aptus Endosystems (Sunnyvale, CA) a clinical-stage medical device company focused on endovascular aneurysm repair, closed a $15M Series D financing. Participants include US Venture Partners and Longitude Capital.

EndoGastric Solutions, Inc.: Series F $30M

Posted in I - Series F, Q - 3Q10, R - NORTH WEST, X - Device (GI), XX - WA

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $30M Series F financing. Participants have included Canaan Partners, Radius Ventures, Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland Oakwood Medical Investors.

Si-Bone, Inc.: Series B $10.6M

Posted in I - Series B, Q - 3Q10, R - WEST, X - Device (Spine), XX - CA

Si-Bone (San Jose, CA) a commercial-stage medical device company focused on minimally-invasive approaches to sacroiliac joint disruptions and degenerative sacroiliitis, closed a $10.6M Series B. Participants include Skyline Ventures.

Complete Genomics, Inc.: Series E $39M

Posted in I - Series E, Q - 3Q10, R - WEST, X - Device (Sequencing), XX - CA

Complete Genomics (Mountain View, CA) a commercial-stage sequencing company building a human genome sequencing center to enable academic and biopharma researchers to conduct large-scale human genome studies, closed a $39M Series E financing. Participants include Sands Capital Management, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.

Poxel, SA: Series A $20.3M

Posted in I - Series A, Q - 3Q10, R - INTERNATIONAL, X - Diabetes, X - Metabolism

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Gemin X Pharmaceuticals, Inc.: Series E $8M

Posted in I - Series E, Q - 3Q10, R - NORTH EAST, X - Oncology, XX - PA

Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Health Market Science, Inc.: Series B $6.1M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - TeleMedicine, XX - PA

Health Market Science (King of Prussia, PA) a commercial-stage biopharma and healthcare data and analytics provider, closed a $6.1M Series B financing. Participants include Cross Atlantic Capital Partners and Edison Venture Fund.

Great Lakes Pharmaceuticals, Inc.: Series B $3.1M

Posted in I - Series B, Q - 3Q10, R - MID WEST, X - Antibacterial, X - Device (Catheter), X - Drug:Device Combo, XX - OH

Great Lakes Pharmaceuticals (Cleveland, OH) a clinical-stage drug:device company focused on catheter-related bloodstream infection, closed a $3.1M Series B financing. Participants include Charter Life Sciences, Early Stage Partners, Ohio Tech Angels and North Coast Angel Fund.